SDA NE100
NE100 is 100 nm particle, the lowest particle size that still fully exhibits emulsion function. This is the first squalene based self-emulsifying oil-in-water adjuvant for use in human when injected intramuscularly or subcutaneously, as well as nasal spray. NE100 squalene-in-water is larger than those of NE60 and NE20, with slight white color, it shows antigen-friendly in that it can be gently mix (low speed) with antigen at any temperature. It shows optimal low viscosity, syringeability, absorptivity, circulating and mobile deposit, safety, antigen presenting and immunogenicity.
NE100 is different from microfluidized emulsion in that NE100 itself is aqueous free oil phase and can be stockpiled many more years before formation of emulsion by mixing with antigen. The surfactant is synthesized and selected for each adjuvant by optimizing its hydrophilic-lipophilic balance, depending on the type of emulsion sought and the fatty phase selected. By the time the end vaccine is produced, or dilutable emulsion to be generated, only a simple, low speed stir mixing is needed to combine NE110 oil phase and antigen to generate uniformly dispersed, micron size oil droplets which ensure maximum emulsion stability and minimal viscosity. Micron size oil droplets also increase the surface area available to antigens. Such tiny particle size as 100 nm is impossible to reach by microfluidizing or homogenizing. Such fine tuned self-emulsifying technology reduced the undesirable side effects associated with microfluidized oil-in-water adjuvants, while eliciting the rapid and strong immune response.
oil-in-water self-emulsifying adjuvants functions by forming mobile deposit of antigen which can be circulated and targeted to immune cells for antigen specific response.
Proper addition of cationic lipids to NE100 leads to saRNA delivery system CNE100.
NE100 can be combined directly with antigen at 1:9 ratio, or can be made to 1:4 emulsion for end users to do further 1:1 dilution with antigen.
SDA NE60
NE60 is a range of ready-to-dilute adjuvants that generate clear formulation of vaccines. Those formulations are a combination of micro-emulsions with the particle size from 10 to 200 nm, with peak at 60 nm. NE60 can be combined directly with antigen at 1:9 ratio, or can be made to 1:4 emulsion for end users to do further 1:1 dilution with antigen.
NE60 can be used to make CNE60 by adding cationic lipids.
NE60 is the only adjuvant that results transparent emulsion human adjuvants for effective therapeutic vaccines.
NE60 can be combined directly with antigen at 1:9 ratio, or can be made to 1:4 emulsion for end users to do further 1:1 dilution with antigen. It can be enriched by QS21 or other immune stimulants.
SDA NE20
NE20 is 20 nm particle, the typical particle size that still fully exhibits emulsion function and optical antigen presentation. This is the first squalene based self-emulsifying oil-in-water adjuvant for use in human when injected intramuscularly or subcutaneously, as well as nasal spray. NE20 is typical white color oil-in-water emulsion, it shows antigen-friendly in that it can be gently mix (low speed) with antigen at any temperature. It shows optimal low viscosity, syringeability, absorptivity, circulating and mobile deposit, safety, antigen presenting and immunogenicity.
NE20 is different from microfluidized emulsion in that NE20 itself is aqueous free oil phase and can be stockpiled many more years before formation of emulsion by mixing with antigen. The surfactant is synthesized and selected for each adjuvant by optimizing its hydrophilic-lipophilic balance, depending on the type of emulsion sought and the fatty phase selected. By the time the end vaccine is produced, or dilutable emulsion to be generated, only a simple, low speed stir mixing is needed to combine NE20 oil phase and antigen to generate uniformly dispersed, micron size oil droplets which ensure maximum emulsion stability and minimal viscosity. Micron size oil droplets also increase the surface area available to antigens. Such tiny particle size as 20 nm is impossible to reach by microfluidizing or homogenizing. Such fine tuned self-emulsifying technology reduced the undesirable side effects associated with microfluidized oil-in-water adjuvants, while eliciting the rapid and strong immune response.
oil-in-water self-emulsifying adjuvants functions by forming mobile deposit of antigen which can be circulated and targeted to immune cells for antigen specific response.
Proper addition of cationic lipids to NE20 leads to saRNA delivery system CNE20.
NE20 can be combined directly with antigen at 1:9 ratio, or can be made to 1:4 emulsion for end users to do further 1:1 dilution with antigen.
SDA NE100
NE100 is 100 nm particle, the lowest particle size that still fully exhibits emulsion function. This is the first squalene based self-emulsifying oil-in-water adjuvant for use in human when injected intramuscularly or subcutaneously, as well as nasal spray. NE100 squalene-in-water is larger than those of NE60 and NE20, with slight white color, it shows antigen-friendly in that it can be gently mix (low speed) with antigen at any temperature. It shows optimal low viscosity, syringeability, absorptivity, circulating and mobile deposit, safety, antigen presenting and immunogenicity.
NE100 is different from microfluidized emulsion in that NE100 itself is aqueous free oil phase and can be stockpiled many more years before formation of emulsion by mixing with antigen. The surfactant is synthesized and selected for each adjuvant by optimizing its hydrophilic-lipophilic balance, depending on the type of emulsion sought and the fatty phase selected. By the time the end vaccine is produced, or dilutable emulsion to be generated, only a simple, low speed stir mixing is needed to combine NE110 oil phase and antigen to generate uniformly dispersed, micron size oil droplets which ensure maximum emulsion stability and minimal viscosity. Micron size oil droplets also increase the surface area available to antigens. Such tiny particle size as 100 nm is impossible to reach by microfluidizing or homogenizing. Such fine tuned self-emulsifying technology reduced the undesirable side effects associated with microfluidized oil-in-water adjuvants, while eliciting the rapid and strong immune response.
oil-in-water self-emulsifying adjuvants functions by forming mobile deposit of antigen which can be circulated and targeted to immune cells for antigen specific response.
Proper addition of cationic lipids to NE100 leads to saRNA delivery system CNE100.
NE100 can be combined directly with antigen at 1:9 ratio, or can be made to 1:4 emulsion for end users to do further 1:1 dilution with antigen.
SDA NE60
NE60 is a range of ready-to-dilute adjuvants that generate clear formulation of vaccines. Those formulations are a combination of micro-emulsions with the particle size from 10 to 200 nm, with peak at 60 nm. NE60 can be combined directly with antigen at 1:9 ratio, or can be made to 1:4 emulsion for end users to do further 1:1 dilution with antigen.
NE60 can be used to make CNE60 by adding cationic lipids.
NE60 is the only adjuvant that results transparent emulsion human adjuvants for effective therapeutic vaccines.
NE60 can be combined directly with antigen at 1:9 ratio, or can be made to 1:4 emulsion for end users to do further 1:1 dilution with antigen. It can be enriched by QS21 or other immune stimulants.
SDA NE20
NE20 is 20 nm particle, the typical particle size that still fully exhibits emulsion function and optical antigen presentation. This is the first squalene based self-emulsifying oil-in-water adjuvant for use in human when injected intramuscularly or subcutaneously, as well as nasal spray. NE20 is typical white color oil-in-water emulsion, it shows antigen-friendly in that it can be gently mix (low speed) with antigen at any temperature. It shows optimal low viscosity, syringeability, absorptivity, circulating and mobile deposit, safety, antigen presenting and immunogenicity.
NE20 is different from microfluidized emulsion in that NE20 itself is aqueous free oil phase and can be stockpiled many more years before formation of emulsion by mixing with antigen. The surfactant is synthesized and selected for each adjuvant by optimizing its hydrophilic-lipophilic balance, depending on the type of emulsion sought and the fatty phase selected. By the time the end vaccine is produced, or dilutable emulsion to be generated, only a simple, low speed stir mixing is needed to combine NE20 oil phase and antigen to generate uniformly dispersed, micron size oil droplets which ensure maximum emulsion stability and minimal viscosity. Micron size oil droplets also increase the surface area available to antigens. Such tiny particle size as 20 nm is impossible to reach by microfluidizing or homogenizing. Such fine tuned self-emulsifying technology reduced the undesirable side effects associated with microfluidized oil-in-water adjuvants, while eliciting the rapid and strong immune response.
oil-in-water self-emulsifying adjuvants functions by forming mobile deposit of antigen which can be circulated and targeted to immune cells for antigen specific response.
Proper addition of cationic lipids to NE20 leads to saRNA delivery system CNE20.
NE20 can be combined directly with antigen at 1:9 ratio, or can be made to 1:4 emulsion for end users to do further 1:1 dilution with antigen.